Monoclonal antibodies such as Bimekizumab, Secukinumab, Ixekizumab, and Brodalumab, which inhibit IL-17A or IL-17RA, have received FDA approval for managing psoriasis and psoriatic arthritis (Simopoulou et al. 2023). This evidence concerns the gene IL17A and psoriatic arthritis.